Results 11 to 20 of about 21,275,692 (207)
For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients.
Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
doaj +2 more sources
Objective: We aimed to investigate to usability and feasibility of perfusion computerized tomography (PCT) in differentiating small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC).
Ömer Özyiğit, Suat Eren
doaj +2 more sources
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj +2 more sources
Angiogenesis and non-small cell lung cancer
Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer.
Walker, R. A. +4 more
core +4 more sources
Non-small-cell lung cancer [PDF]
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours, represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking remains the main risk factor for developing this disease, but radon exposure and air ...
Gridelli, C +8 more
openaire +5 more sources
Afatinib treatment in advanced non-small cell lung cancer
Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj +1 more source
Non–Small Cell Lung Cancer [PDF]
Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment.
David S, Ettinger +35 more
openaire +4 more sources
Non-small cell lung cancer [PDF]
Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagnosis and performance status of patients. In the low clinical stages a surgical solution is indicated.
Jana, Skřičková +2 more
openaire +2 more sources
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention ...
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
doaj +1 more source
LncRNAs in Non-Small-Cell Lung Cancer [PDF]
Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in 2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite improvement in the management of NSCLC, most patients are diagnosed at advanced stage and the five-year survival remains around 15%.
Lucy Ginn +3 more
openaire +5 more sources

